"label","rationale","uuid:ID","name","description","id","instanceType"
"","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","f1622c8f-204e-49fa-93cf-5079dfcf1856","Study Design 1","The main design for the study","StudyDesign_1","StudyDesign"
